Hong Kong-listed biopharmaceutical stocks rebounded, with Yiming Onco (01541.HK) rising over 7%, Antengene (06996.HK) rising over 6%, Connoya (02162.HK) and Ascletis Pharma (01672.HK) both rising over 5%, and Laikai Pharma (02105.HK) and others following suit.